Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
1194044-20-6
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:hasInChIKey |
QZJQJZQJQJQJQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C22H22Cl2N2O2
|
| gptkbp:hasSMILES |
C1=CC(=C(C=C1Cl)Cl)C2=CC(=O)N(C3=NC4=C(C=CC=C4Cl)N3)C2=O
|
| gptkbp:hasTherapeuticUse |
anticancer agent
treatment of solid tumors treatment of acute myeloid leukemia |
| https://www.w3.org/2000/01/rdf-schema#label |
LY2090314
|
| gptkbp:isExperimentalDrug |
true
|
| gptkbp:isInClinicalTrialPhase |
Phase II
|
| gptkbp:IUPACName |
3-(6-chloro-1H-benzimidazol-2-yl)-4-(2,4-dichlorophenyl)-1H-pyrrole-2,5-dione
|
| gptkbp:molecularWeight |
435.24 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
46209416 DB12107 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
GSK-3 inhibitor LY2090314
|
| gptkbp:target |
gptkb:GSK-3
|
| gptkbp:bfsParent |
gptkb:GSK-3β
|
| gptkbp:bfsLayer |
7
|